Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.

Novo Nordisk (NVO) said on Wednesday that its emissions rose by nearly a quarter in 2024 and will continue to increase up to 2030 as production increases to meet demand for its obesity blockbuster ...

The firm then sold three of Catalent's plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of the deal, to help the Danish drugmaker ramp up supplies of ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

It was frequently used in Canada by pharmacies during the COVID-19 pandemic when manufactured supplies of children ... company says Ozempic maker Novo Nordisk says it’s the only company ...

This story incorporates reporting fromdevdiscourse, WJON and KIMT.Novo Nordisk has settled a lawsuit with Minnesota, agreeing to cap insulin prices at $35 per monthly prescription. This legal ...

Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...